Neurocrine biosciences reports first quarter 2022 financial results and reiterates 2022 financial guidance

Ingrezza® (valbenazine) first quarter net product sales of $303 million ingrezza® (valbenazine) 2022 net product sales guidance reiterated at $1.25 - $1.35 billion san diego , may 4, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the first quarter ended march 31, 2022 and reiterated financial guidance for 2022. "ingrezza's first quarter performance reflects the opportunity we have to help patients living with tardive dyskinesia (td).
NBIX Ratings Summary
NBIX Quant Ranking